Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

(2013) Michael W. Deininger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study

(2013) Suzanne Dunne et al.   BMC Pharmacology & Toxicology

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

(2012) J. P. Radich et al.   BLOOD

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms

(2010) Laura E. Panattoni   JOURNAL OF HEALTH ECONOMICS

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of European Pharmaceutical Price Regulation on Generic Price Competition

(2010) Jaume Puig-Junoy   PHARMACOECONOMICS

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

(2009) Pierre Emmanuel Paradis et al.   CURRENT MEDICAL RESEARCH AND OPINION

Trends in generic prescribing and dispensing in Europe

(2008) Steven Simoens   Expert Review of Clinical Pharmacology